Table 7.
Activity of Selected Antimicrobial Agents Tested Against 6467 Stenotrophomonas maltophilia Isolates by Geographic Region
| CLSIa | EUCASTa | |||||
|---|---|---|---|---|---|---|
| Geographic Region (No. Tested) Antimicrobial Agent | MIC50,mg/L | MIC90, mg/L | %S | %R | %S | %R |
| All geographic regions (6467) | ||||||
| Levofloxacin (6460) | 1 | 4 | 81.5 | 9.7 | b | b |
| Minocycline (3868) | ≤1 | 2 | 99.5 | 0.2 | b | b |
| Trimethoprim-sulfamethoxazole (6453) | ≤0.5 | 1 | 95.6 | 4.4 | 96.2 | 3.8 |
| Asia-Pacific (613) | ||||||
| Levofloxacin (613) | 1 | 4 | 80.9 | 9.6 | b | b |
| Minocycline (363) | ≤1 | 2 | 99.2 | 0.3 | b | b |
| Trimethoprim-sulfamethoxazole (612) | ≤0.5 | ≤0.5 | 93.8 | 6.2 | 94.1 | 5.9 |
| Europe (2038) | ||||||
| Levofloxacin (2035) | 1 | 4 | 83.6 | 8.4 | b | b |
| Minocycline (1294) | ≤1 | ≤1 | 99.2 | 0.2 | b | b |
| Trimethoprim-sulfamethoxazole (2033) | ≤0.5 | 1 | 95.8 | 4.2 | 96.3 | 3.7 |
| Latin America (704) | ||||||
| Levofloxacin (703) | 1 | 4 | 87.8 | 5.1 | b | b |
| Minocycline (342) | ≤1 | ≤1 | 99.7 | 0.0 | b | b |
| Trimethoprim-sulfamethoxazole (701) | ≤0.5 | 1 | 94.4 | 5.6 | 94.7 | 5.3 |
| North America (3112) | ||||||
| Levofloxacin (3109) | 1 | >4 | 78.7 | 11.6 | b | b |
| Minocycline (1869) | ≤1 | 2 | 99.6 | 0.2 | b | b |
| Trimethoprim-sulfamethoxazole (3107) | ≤0.5 | 1 | 96.1 | 4.4 | 96.9 | 3.1 |
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration; R, resistant; S, susceptible.
bBreakpoints not determined by EUCAST [30].